Cryoport Inc
$ 8.53
0.59%
26 Feb - close price
- Market Cap 424,584,000 USD
- Current Price $ 8.53
- High / Low $ 8.60 / 8.34
- Stock P/E N/A
- Book Value 9.45
- EPS -1.25
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.11 %
- 52 Week High 11.45
- 52 Week Low 4.58
About
Cryoport, Inc., a life sciences services company, provides temperature controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and Asia Pacific. The company is headquartered in Brentwood, Tennessee.
Analyst Target Price
$13.22
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-12 | 2025-05-05 | 2025-03-10 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-08 | 2023-08-09 | 2023-05-04 | 2023-02-23 |
| Reported EPS | -0.18 | -0.28 | -0.3836 | -0.4271 | -0.02 | -0.29 | -0.43 | -1.31 | -0.31 | -0.42 | -0.16 | -0.24 |
| Estimated EPS | -0.24 | -0.27 | -0.2577 | -0.3064 | -0.29 | -0.39 | -0.35 | -0.29 | -0.3 | -0.24 | -0.19 | -0.19 |
| Surprise | 0.06 | -0.01 | -0.1259 | -0.1207 | 0.27 | 0.1 | -0.08 | -1.02 | -0.01 | -0.18 | 0.03 | -0.05 |
| Surprise Percentage | 25% | -3.7037% | -48.8553% | -39.393% | 93.1034% | 25.641% | -22.8571% | -351.7241% | -3.3333% | -75% | 15.7895% | -26.3158% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CYRX
2026-02-24 10:53:30
CryoPort (NASDAQ:CYRX) is scheduled to release its Q4 2025 earnings after market close on Tuesday, March 3rd, with analysts anticipating a loss of ($0.19) per share and revenue of $42.9240 million. The company's stock has been trading down, with recent insider selling by a director. Institutional investors have also been active, while analysts have a "Moderate Buy" consensus rating with an average price target of $12.83.
2026-02-20 11:50:11
Cryoport Inc. (NASDAQ: CYRX) is showing divergent sentiment across all horizons, suggesting choppy conditions with no clear price positioning signal and elevated downside risk. Stock Traders Daily's AI models have generated three distinct trading strategies: a Position Trading Strategy (LONG), a Momentum Breakout Strategy (BREAKOUT), and a Risk Hedging Strategy (SHORT), each with specific entry, target, and stop loss points. Multi-timeframe analysis indicates neutral near-term, weak mid-term, and strong long-term signals, with their AI-generated signals providing detailed support and resistance levels.
2026-02-18 09:57:17
Readystate Asset Management LP reduced its stake in CryoPort, Inc. (NASDAQ:CYRX) by 37.2%, selling 180,605 shares and retaining 304,529 shares. This sale, valued at $2.887 million, was disclosed in a recent SEC filing. Additionally, CryoPort director Ramkumar Mandalam sold 11,570 shares, decreasing his ownership by 12.53%.
2026-02-17 12:57:55
Cryoport, Inc. (Nasdaq: CYRX) announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 3, 2026, after U.S. markets close. The company will also release a detailed review document and host a questions-and-answers conference call the same day at 5:00 p.m. ET.
2026-02-11 13:57:58
Cryoport (NASDAQ: CYRX) has launched the MVE Fusion® 800 Series, a new self-sustaining cryogenic freezer that eliminates the need for a continuous liquid nitrogen supply. This lab-sized unit maintains temperatures at or below -150°C, fits through standard doorways, and is aimed at facilities like research labs, hospital pharmacies, and biorepositories. The company believes this award-winning technology offers significant flexibility and cost benefits for biological material storage.
2026-02-11 13:57:58
Cryoport's MVE Biological Solutions has launched the new Fusion® 800 Series, a self-sustaining cryogenic freezer that offers high-capacity storage, flexibility, and cost benefits in limited space environments. This innovative product eliminates the need for a continuous liquid nitrogen supply, providing exceptional reliability and safety in a compact design. The Fusion 800 is ideal for various medical and biological facilities, maintaining steady state temperatures at or below -150°C and addressing a longstanding challenge in cryogenic storage.
